ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

GPC3-targeted Plasmid DNA Vaccine NWRD06

Also written as “NWRD06 administered by electroporation”, “1mg NWRD06 administered by electroporation” and “4mg NWRD06 administered by electroporation”.

Its studies are mostly in Carcinoma, Hepatocellular, led by Newish Biotech (Wuxi).

Furthest: phase 2, since Dec 23, 20252 company-led studies, 2 open or runningNext primary completion: Dec 31, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Newish Biotech (Wuxi)22 open or runningphase 2since Dec 23, 2025Sep 27, 2023Dec 31, 2028phase 2 · NCT07324304

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 27, 2023First study: phase 1 study in Carcinoma, HepatocellularFirst studyNCT06088459 · 9 planned · China
  2. Dec 23, 2025Phase 2 study in Carcinoma, HepatocellularPhase 2 reachedNCT07324304 · 30 planned · China

Ahead

  1. Dec 31, 2028Primary completion: phase 2 study in Carcinoma, HepatocellularNCT07324304

TargetBeta

GPC3 →read by rule
“A plasmid DNA therapeutic cancer vaccine encoding glypican-3 (GPC3), ”NCIt, by rule

Other programs on GPC3

ProgramCompanyFurthest phaseStudies
Anti-GPC3/Anti-4-1BB Bispecific Antibody BGB-B2033ruleBeOne Medicinesphase 33
codrituzumabHoffmann-La Rochephase 23
Actinium Ac 225 GPC3-targeted Peptide RYZ801Bristol-Myers Squibbphase 21
Anti-GPC3 T Cell-engaging Antibody AZD9793AstraZenecaphase 21
Anti-GPC3 Antibody-drug Conjugate ZW251ruleZymeworksphase 11
Anti-GPC3 Antibody-drug Conjugate ABBV-324AbbViephase 11
Actinium Ac 225 GPC3-targeted Antibody Conjugate BAY 3547926ruleBayerphase 11
ACE723ruleacepodia-biotech-incphase 11
TQB6426ruleSino Biopharmaceuticalphase 11

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07324304Carcinoma, Hepatocellular · China2RecruitingDec 31, 202830
NCT06088459Carcinoma, Hepatocellular · China1RecruitingDec 20249

How it is read

Names in the registry

  • “NWRD06 administered by electroporation”, 1 entry
  • “1mg NWRD06 administered by electroporation”, 1 entry
  • “4mg NWRD06 administered by electroporation”, 1 entry
  • “8mg NWRD06 administered by electroporation”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.